Patents by Inventor Damian Jay WHITE

Damian Jay WHITE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND MATERIALS FOR DETERMINING THE EFFICACY OF PROSTATE CANCER THERAPIES
    Publication number: 20140135232
    Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.
    Type: Application
    Filed: December 18, 2013
    Publication date: May 15, 2014
    Applicant: CALDERA HEALTH LIMITED
    Inventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
  • Methods and materials for the diagnosis of prostate cancers
    Patent number: 8703127
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: April 22, 2014
    Assignee: Caldera Health Limited
    Inventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
  • Methods and materials for the diagnosis of prostate cancers
    Patent number: 8658164
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 25, 2014
    Assignee: Caldera Health Limited
    Inventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
  • Methods and materials for the diagnosis of prostate cancers
    Patent number: 8658166
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: February 25, 2014
    Assignee: Caldera Health Limited
    Inventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
  • Methods and materials for determining the efficacy of prostate cancer therapies
    Patent number: 8632971
    Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: January 21, 2014
    Assignee: Caldera Health Limited
    Inventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
  • METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS
    Publication number: 20130116133
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 9, 2013
    Applicant: CALDERA HEALTH LIMITED
    Inventors: James Douglas Watson, Richard Llewellyn Sydney Forster, Damian Jay White
  • METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS
    Publication number: 20130115604
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 9, 2013
    Applicant: CALDERA HEALTH LIMITED
    Inventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
  • METHODS AND MATERIALS FOR DETERMINING THE EFFICACY OF PROSTATE CANCER THERAPIES
    Publication number: 20130116140
    Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.
    Type: Application
    Filed: August 30, 2012
    Publication date: May 9, 2013
    Applicant: CALDERA HEALTH LIMITED
    Inventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE
  • METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS
    Publication number: 20130116131
    Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 9, 2013
    Applicant: CALDERA HEALTH LIMITED
    Inventors: James Douglas WATSON, Richard Llewellyn Sydney FORSTER, Damian Jay WHITE